This thesis deals in general with mergers & acquisitions in the CRO industry, and more
specifically with reasons for M&A, success factors during the M&A process, and why
M&A can fail in the Contract Research Organization industry.
The pharmaceutical industry faces increasing obstacles in respect to the development and
introduction of new medications. That has to do with stricter requirements for admission
and sharper controls by authorities. Today, the research and development of a new drug
can easily consume more than $800 million and lasting between 10 and 15 years. Due to
these admission, money and time pressures, pharmaceutical companies are looking for an
alternative in the drug development process. A very popular alternative is the outsourcing
or in-house working with Contract Research Organizations (CRO). Contract Research
Organizations are specialized in coordination and monitoring of drug development
activities. Due to their focus they often offer a more sophisticated and faster process.
Demographic changes, chronic diseases like cancer and diabetes, and completely new
cluster of symptoms demand new therapeutically treatments. The size of the CRO market
in 2012 was around $32 billion and had an estimated market growth of around 9 – 12% for
2013. Increased outsourcing and allocation of R&D money towards CRO reflects a driving
force for prospective growth. To benefit from the good industry outlooks CROs adjust
their service offerings and strengthen their competitive situation.
More and more Contract Research Organizations consider mergers & acquisitions as a
vital solution to achieve their objectives. Since couple of years we can observe an
increased number of deals. Large corporations can close the gaps in the internal service
pipeline and smaller firms can use mergers as a financial exit.
However, many M&A activities are considered as ineffective and contra-productive for
the shareholder value – either destroy or merely add. Depending on the study, the numbers
of M&A failures vary from 50% to even 80%. Possible reasons may be not enough
integration planning and unrealistic expectations on the cost and time. The reality shows
that it is not that easy to cut costs by simple combining two departments after a merger or
acquisition. Additionally, we can see that mergers and acquisitions basically not succeed
during the actual process.[...]
Table of Contents
1. Merger & Acquisitions Fundamentals
1.1 Definition and History
1.2 Types and history of Merger & Acquisitions
1.3 Recent M&A Trends
2. Contract Research Organization Industry
2.1 The Drug Development Process
2.2 Fundamentals of Contract Research Organizations
2.3 Strategic Analysis of the Drug Development Market
2.3.1 Macro environment – PESTEL
2.3.2Microenvironment - Porter
2.4 Growth Strategies in CRO Industry
2.4.1 Structural Changes in the CRO Industry
2.4.2 Growth Strategies
2.4.3 Mergers & Acquisitions in the CRO Industry
3. Explanatory Approaches and Motives for M&A
3.1 Strategic Motives
3.1.1 Synergy
3.1.2 Market Power
3.1.3 Portfolio Hypotheses / Diversification
3.2 Financial Motives
3.2.1 Valuation Theory
3.2.2 Tax Hypothesis
3.3 Managerial Motives
3.3.1 Hubris
3.3.2 Agency Hypothesis
4. Success Factors for the Merger & Acquisitions process
4.1 Merger & Acquisitions Process
4.1.1 The Planning Phase
4.1.2 The Execution Phase
4.1.3 The Integration Phase
4.2 Potential Success Factors during the M&A process
4.2.1 Potential Success Factors in the Strategic Planning Phase
4.2.2 Potential Success Factors in the Execution Phase
4.2.3 Potential Success Factors in the Integration Phase
5. Case Study: Merger & Acquisitions in the CRO Industry
5.1 Data & Methodology
5.2 Why M&A occur in the CRO Industry
5.3 Potential Success Factors for the M&A process in the CRO industry
5.3.1 Strategic Planning Phase
5.3.2 Execution Phase
5.3.3 Integration Phase
5.4 Reasons for success failures for the M&A process in the CRO industry
5.5 Determinants and evaluation for success after the M&A
6. Conclusion and Recommendations
Objectives and Research Topics
This thesis examines the role of mergers and acquisitions (M&A) within the Contract Research Organization (CRO) industry, focusing on the strategic motives, critical success factors across different phases of the M&A process, and the identification of reasons for potential failure in this specialized sector.
- Analysis of the pharmaceutical drug development process and the role of CROs.
- Evaluation of theoretical motives for M&A (strategic, financial, and managerial).
- Examination of success factors categorized by planning, execution, and integration phases.
- Case study utilizing survey data from industry managers to evaluate theoretical findings.
- Recommendations for successful M&A implementation in the CRO market.
Excerpt from the Book
4.1.2 The Execution Phase
The execution phase consists of three main parts. It contains the first contact between the firms, the negotiation stage and finally the closing.
The first contact with the potential target can be made by the service contractor or directly through the company itself. Usually the contact is established between the companies upper level management. The first contact is important to build trust and relationships for further negotiations. Additionally, management of both firms can discuss about the first business issues like common objectives and an approximately asking price. Generally, engaged parties sign a confidentially agreement and record the first results in term sheets. If the parties basically agree on the M&A process they sign a Letter of Intent (LOI).
After the first contact is established the negation phase begins, which is one of the most complex parts of the entire M&A process. The parties have to refine the valuation, structure the deal, perform a due diligence, develop a financing plan and finally decide whether to close the deal or walk away.
Summary of Chapters
1. Merger & Acquisitions Fundamentals: This chapter provides an overview of the definition and historical waves of M&A, establishing the foundational terminology for the study.
2. Contract Research Organization Industry: This section details the drug development process and the role of CROs, followed by a structural analysis using PESTEL and Porter’s Five Forces.
3. Explanatory Approaches and Motives for M&A: This chapter categorizes M&A drivers into strategic, financial, and managerial motives based on academic theory.
4. Success Factors for the Merger & Acquisitions process: This chapter examines the ideal M&A process, broken down into planning, execution, and integration, identifying potential success factors for each.
5. Case Study: Merger & Acquisitions in the CRO industry: This chapter presents original empirical research via a survey of industry managers to validate theoretical success factors and reasons for failure.
6. Conclusion and Recommendations: This concluding chapter synthesizes the theoretical and empirical findings to offer practical guidance for M&A strategies within the CRO sector.
Keywords
Mergers and Acquisitions, M&A, Contract Research Organization, CRO, Drug Development, Strategic Motives, Success Factors, Integration Management, Due Diligence, Pharmaceutical Industry, Market Power, Synergy, Corporate Strategy, Clinical Trials.
Frequently Asked Questions
What is the primary focus of this thesis?
The thesis focuses on the role of M&A within the Contract Research Organization (CRO) industry, specifically investigating the motives for these transactions, success factors during the process, and common reasons for failure.
What are the central thematic areas of the research?
The central themes include the fundamental definitions of M&A, the structural dynamics of the CRO industry, theoretical frameworks for M&A motives, and the practical implementation of M&A processes, validated through a survey.
What is the primary research goal?
The primary goal is to evaluate which specific factors identified in academic literature contribute to the success of M&A transactions within the CRO industry and to identify how these firms can avoid common pitfalls.
Which scientific methodology is employed?
The methodology combines a thorough literature review of academic sources and management studies with an empirical case study utilizing a survey of top-level managers in the CRO industry.
What is covered in the main section of the work?
The main sections cover the history and types of M&A, the strategic analysis of the drug development market, motives for M&A, and detailed success factors across the planning, execution, and integration phases.
Which keywords best characterize this work?
Key terms include M&A, Contract Research Organization, drug development, success factors, integration management, and strategic alliances.
How does the author define a "horizontal consolidation" in the first merger wave?
The author defines it as the combination of two competitors from the same industry, often leading to monopolistic market structures, which characterized about 80% of all M&A activity in the late 19th and early 20th century.
Why is the CRO industry considered knowledge-intensive according to the research?
The industry is considered knowledge-intensive because CROs rely on ongoing genetic research, high-throughput screening technologies, and specialized personnel, making the transfer of know-how and the retention of key staff critical success factors.
- Quote paper
- Bachelor of Business Administration Jakob Miera (Author), 2013, Mergers & Acquisitions in the Contract Research Organization Industry, Munich, GRIN Verlag, https://www.grin.com/document/262330
